As you might know, The Oncology Institute, Inc. (NASDAQ:TOI) just kicked off its latest first-quarter results with some very strong numbers. Results overall were solid, with revenues arriving 3.8% better than analyst forecasts at US$147m. Higher revenues also resulted in substantially lower statutory losses which, at US$0.02 per share, were 3.8% smaller than the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Oncology Institute after the latest results.

Taking into account the latest results, the current consensus from Oncology Institute's four analysts is for revenues of US$660.0m in 2026. This would reflect a major 21% increase on its revenue over the past 12 months. Losses are predicted to fall substantially, shrinking 63% to US$0.13. Before this earnings announcement, the analysts had been modelling revenues of US$647.8m and losses of US$0.30 per share in 2026. While the revenue estimates were largely unchanged, sentiment seems to have improved, with the analysts upgrading their numbers and making a considerable decrease in losses per share in particular.

These new estimates led to the consensus price target rising 7.7% to US$7.00, with lower forecast losses suggesting things could be looking up for Oncology Institute. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Oncology Institute at US$8.00 per share, while the most bearish prices it at US$5.00. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Oncology Institute shareholders.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Oncology Institute's rate of growth is expected to accelerate meaningfully, with the forecast 29% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 21% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 4.7% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Oncology Institute is expected to grow much faster than its industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Oncology Institute going out to 2027, and you can see them free on our platform here.

Even so, be aware that Oncology Institute is showing 3 warning signs in our investment analysis , and 1 of those is a bit concerning...

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.